C4 Therapeutics (CCCC) Amortizatization of Intangibles (2019 - 2026)
C4 Therapeutics' quarterly Amortizatization of Intangibles came in at $1.1 million in Q1 2026, up 39.08% year-on-year from $783000.0 in Q1 2025, and down 23.79% quarter-over-quarter from $1.4 million in Q4 2025.
C4 Therapeutics has reported Amortizatization of Intangibles for 8 years, with the latest figure at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 39.08% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.7 million (up 19.82% YoY), and the FY2025 full-year result was $6.4 million, changed 0.2% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $1.1 million, down from $1.4 million in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $4.0 million in Q3 2022, with the low at -$3.7 million in Q4 2022.
- Average Amortizatization of Intangibles over 5 years is $1.2 million, with a median of $1.4 million recorded in 2024.
- Year-over-year, Amortizatization of Intangibles tumbled 2175.0% in 2022 and surged 797.16% in 2024.
- Tracing CCCC's Amortizatization of Intangibles over 5 years: stood at -$3.7 million in 2022, then soared by 142.46% to $1.6 million in 2023, then soared by 34.74% to $2.1 million in 2024, then sank by 32.15% to $1.4 million in 2025, then dropped by 23.79% to $1.1 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $1.1 million (Q1 2026), $1.4 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.09 Mn |
| Mar 31, 2026 | 1.09 Mn |
| Dec 31, 2025 | 1.43 Mn |
| Dec 31, 2025 | 1.43 Mn |
| Sep 30, 2025 | 3.64 Mn |
| Sep 30, 2025 | 3.64 Mn |
| Jun 30, 2025 | 581,000.00 |
| Jun 30, 2025 | 581,000.00 |
| Mar 31, 2025 | 783,000.00 |
| Mar 31, 2025 | 783,000.00 |
| Dec 31, 2024 | 2.11 Mn |
| Dec 31, 2024 | 2.11 Mn |
| Sep 30, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | 1.56 Mn |
| Dec 31, 2023 | 1.56 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 2.87 Mn |
| Jun 30, 2023 | 2.87 Mn |
| Mar 31, 2023 | 176,000.00 |
| Mar 31, 2023 | 176,000.00 |
| Dec 31, 2022 | -3.68 Mn |
| Dec 31, 2022 | -3.68 Mn |
| Sep 30, 2022 | 4.04 Mn |
| Sep 30, 2022 | 4.04 Mn |
| Jun 30, 2022 | -830,000.00 |
| Jun 30, 2022 | -830,000.00 |
| Mar 31, 2022 | 1.18 Mn |
| Mar 31, 2022 | 1.18 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | -1.39 Mn |
| Sep 30, 2021 | -1.39 Mn |
| Jun 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 40,000.00 |
| Mar 31, 2021 | 320,000.00 |
| Mar 31, 2021 | 320,000.00 |
| Dec 31, 2020 | -134,000.00 |
| Dec 31, 2020 | -134,000.00 |
| Sep 30, 2020 | 203,000.00 |
| Sep 30, 2020 | 203,000.00 |
| Jun 30, 2020 | -273,000.00 |
| Jun 30, 2020 | -273,000.00 |
| Mar 31, 2020 | 298,000.00 |
| Mar 31, 2020 | 298,000.00 |
| Dec 31, 2019 | -1.18 Mn |
| Dec 31, 2019 | -1.18 Mn |